Paricalcitol, a selective VDR agonist, effectively suppresses PTH mRNA and inhibits parathyroid cell growth, treating secondary hyperparathyroidism in CKD. It's also associated with lower morbidity and improved survival rates compared to other VDRAs, with a favorable side-effect profile. Additionally, paricalcitol exhibits anti-inflammatory effects, potentially beneficial in managing CKD-related inflammation.
Tags: buy Paricalcitol | purchase Paricalcitol | Paricalcitol cost | order Paricalcitol | Paricalcitol chemical structure | Paricalcitol in vivo | Paricalcitol in vitro | Paricalcitol formula | Paricalcitol molecular weight